Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Doxa AB is a Swedish company that specializes in the production and development of advanced dental and medical products. The company's primary focus is on delivering innovative solutions within the healthcare sector, particularly through its widely recognized products for dental professionals. Doxa's flagship product, Ceramir Crown & Bridge, is renowned for its bioactive and biocompatible properties, offering sustainable and effective solutions for dental restorations. This distinctive product underscores Doxa's commitment to enhancing dental care while prioritizing patient safety and comfort. Operating in the niche yet vital field of dental materials, Doxa AB significantly impacts the healthcare industry by improving procedural outcomes and patient experiences in dentistry. The company's ongoing research and development efforts are crucial in driving innovation in dental technology and expanding its product offerings. With a firm focus on quality and sustainability, Doxa AB plays a pivotal role in advancing dental science and supporting the provision of high-quality healthcare services globally.
kr 0.00
+kr 0.00 (+4.26%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-306.90% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 31.0% YoY with margins expanding 3180.8pp.
Net debt of kr 1.50B represents 5.6x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 7M
▲ +31.0% YoY
Net Income (TTM)
-kr 313M
▲ +80.5% YoY
Op. Margin
-2128.36%
▲ +3180.8pp YoY
ROIC
-1.04%
▲ +8.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 470M
▲ +518.4% YoY
Op. Cash Flow (TTM)
-kr 410M
▲ +672.3% YoY
Net Debt
kr 1.50B
Cash & Equiv.
kr 52M
3Y CAGR: +57.5%
Continue Research
Doxa AB (DOXA.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Doxa AB scores 11/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Doxa AB scores 11 out of 100 on Intrinsiqq's quality score, passing 0 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -2,128.4% operating margin and a -1.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh DOXA.XSTO's valuation and scores 11/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.